Cargando…
Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of neoplastic B lymphocytes with high levels of Wnt5a in the plasma. Currently, the cell source of Wnt5a remains controversial. The receptor of Wnt5a is ROR1, whose expression is associated with disease progression and resistanc...
Autores principales: | Guo, Yao, Pei, Hanzhong, Lu, Bo, Zhang, Dengyang, Zhao, Yuming, Wu, Fuqun, Sun, Honghua, Huang, Junbin, Li, Peng, Yi, Chenju, Zhu, Chengming, Pan, Yihang, Wu, Shunjie, Chen, Chun, Xu, Xiaojun, Chen, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873424/ https://www.ncbi.nlm.nih.gov/pubmed/35210425 http://dx.doi.org/10.1038/s41420-022-00884-y |
Ejemplares similares
-
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
por: Zhang, Dengyang, et al.
Publicado: (2021) -
The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019) -
The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022) -
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022) -
Aberrant Wnt Signaling in Leukemia
por: Staal, Frank J. T., et al.
Publicado: (2016)